AbbVie Deal Signals Growing Pharma Interest in Psychedelics

AbbVie's $1.2 billion deal for a depression asset is signaling a major shift, with large pharmaceutical firms now seriously eyeing the psychedelic therapeutics market.

By Anna Kuznetsov